Beyond Air reported fiscal year 2026 revenue of $7.7 million, a 107% increase driven by new hospital adoption and strong customer retention. The company posted a gross profit of $300,000 compared to a $1.7 million loss last year, while R&D and SG&A expenses fell 39% and 27% respectively following restructuring. Net loss narrowed to $33.2 million from $46.6 million. Management provided first-time calendar year 2026 revenue guidance of $8 million and calendar year 2027 guidance of $16 million to $18 million, assuming FDA approval and commercial launch of the second-generation LungFit PH system. The Gen 2 device, if approved, is expected to expand the U.S. addressable market four-fold to approximately $400 million by adding transport capability. The company also announced a 1-for-20 reverse stock split to regain Nasdaq compliance by July 31, 2026.
Beyond Air IncRevenue growth, improved margins, narrowed losses, and forward guidance indicate financial improvement.